MedTrace Logo

Conventional Adjuvant Temozolomide With Dose Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma

NCT01364064 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1153

Last updated 2016-02-25

No results posted yet for this study

Summary

This is a Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose Intensive Temozolomide in Patients with Newly Diagnosed Glioblastoma.

Conditions

Interventions

DRUG

TMZ

Comparing conventional adjuvant Temozolomide with dose intensive Temozolomide

Sponsors & Collaborators

  • Radiation Therapy Oncology Group

    collaborator NETWORK

  • King Faisal Specialist Hospital & Research Center

    lead OTHER

Principal Investigators

  • Naseer Al-Rajhi · KFSH & RC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2008-06-30
Completion
2008-06-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01364064 on ClinicalTrials.gov